CO6811814A2 - Vacuna de virus dengue inactivado - Google Patents
Vacuna de virus dengue inactivadoInfo
- Publication number
- CO6811814A2 CO6811814A2 CO13277999A CO13277999A CO6811814A2 CO 6811814 A2 CO6811814 A2 CO 6811814A2 CO 13277999 A CO13277999 A CO 13277999A CO 13277999 A CO13277999 A CO 13277999A CO 6811814 A2 CO6811814 A2 CO 6811814A2
- Authority
- CO
- Colombia
- Prior art keywords
- dengue virus
- virus vaccine
- vaccine inactivated
- inactivated
- dengue
- Prior art date
Links
- 229940023605 dengue virus vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490205P | 2011-05-26 | 2011-05-26 | |
US201161570966P | 2011-12-15 | 2011-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6811814A2 true CO6811814A2 (es) | 2013-12-16 |
Family
ID=46148894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13277999A CO6811814A2 (es) | 2011-05-26 | 2013-11-26 | Vacuna de virus dengue inactivado |
Country Status (15)
Country | Link |
---|---|
US (1) | US20140112953A1 (es) |
EP (1) | EP2714076A1 (es) |
JP (1) | JP2014515367A (es) |
KR (1) | KR20140033171A (es) |
CN (2) | CN107050445A (es) |
AU (2) | AU2012260807B2 (es) |
BR (1) | BR112013030236A2 (es) |
CA (1) | CA2837145A1 (es) |
CO (1) | CO6811814A2 (es) |
EA (1) | EA201391515A1 (es) |
IL (1) | IL229307A0 (es) |
MX (1) | MX349119B (es) |
PE (1) | PE20140646A1 (es) |
SG (1) | SG194950A1 (es) |
WO (1) | WO2012160199A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016145149A1 (en) * | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
CA2991212A1 (en) | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
MX2018003757A (es) | 2015-09-26 | 2018-09-21 | Primevax Immuno Oncology Inc | Composiciones y metodos para producir celulas dendriticas. |
GB201522068D0 (en) | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
BE1024160B9 (fr) * | 2015-12-22 | 2017-12-06 | Glaxosmithkline Biologicals Sa | Formulation immunogène |
US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
CA3082779A1 (en) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Combination immunotherapies for treatment of cancer |
EP3565567A4 (en) * | 2017-01-04 | 2020-07-29 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS |
CN107140625A (zh) * | 2017-06-14 | 2017-09-08 | 中国海洋大学 | 一种利用植物油制备石墨烯薄膜的方法 |
MY194449A (en) | 2017-11-03 | 2022-11-30 | Takeda Vaccines Inc | Zika vaccines and immunogenic compositions, and methods of using the same |
PE20210654A1 (es) | 2017-12-07 | 2021-03-31 | Merck Sharp & Dohme | Formulaciones de composiciones de vacuna contra el virus del dengue |
BR112022015710A2 (pt) * | 2020-02-27 | 2022-09-27 | Takeda Vaccines Inc | Método para remover dna de célula hospedeira a partir da preparação de vírus |
CN112546213A (zh) * | 2020-12-31 | 2021-03-26 | 中国医学科学院医学生物学研究所 | 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法 |
CN113750228B (zh) * | 2021-09-25 | 2024-02-20 | 大连理工大学 | 一种冷冻保护剂在铝佐剂中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6254873B1 (en) * | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
CZ2003930A3 (cs) * | 2000-10-02 | 2003-08-13 | Glaxosmithkline Biologicals S. A. | Vakcinační prostředek obsahující štěpený virus s obalem |
DK3417875T3 (da) * | 2003-02-10 | 2020-08-31 | Biogen Ma Inc | Immunglobulinformulering og fremgangsmåde til fremstilling deraf |
ES2647491T3 (es) * | 2004-05-21 | 2017-12-21 | Novartis Vaccines And Diagnostics, Inc. | Vectores del alfavirus para las vacunas del virus de la gripe |
JP5138601B2 (ja) * | 2005-11-21 | 2013-02-06 | サノフィ パストゥール リミテッド | 組換えウイルス安定化製剤 |
US8084039B2 (en) * | 2007-04-06 | 2011-12-27 | Inviragen, Inc. | Methods and compositions for live attenuated viruses |
ES2564183T3 (es) * | 2008-09-29 | 2016-03-18 | Cadila Pharmaceuticals Ltd. | Adyuvantes de vacuna |
ES2649020T3 (es) * | 2009-02-17 | 2018-01-09 | Glaxosmithkline Biologicals S.A. | Vacuna inactivada del virus del dengue con adyuvante libre de aluminio |
US9005633B2 (en) * | 2009-07-17 | 2015-04-14 | The United States Of America As Represented By The Secretary Of The Navy. | Psoralen-inactivated viral vaccine and method of preparation |
US8557253B2 (en) * | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
-
2012
- 2012-05-25 SG SG2013084298A patent/SG194950A1/en unknown
- 2012-05-25 US US14/119,902 patent/US20140112953A1/en not_active Abandoned
- 2012-05-25 EA EA201391515A patent/EA201391515A1/ru unknown
- 2012-05-25 JP JP2014511908A patent/JP2014515367A/ja active Pending
- 2012-05-25 PE PE2013002709A patent/PE20140646A1/es not_active Application Discontinuation
- 2012-05-25 BR BR112013030236A patent/BR112013030236A2/pt not_active Application Discontinuation
- 2012-05-25 CA CA2837145A patent/CA2837145A1/en not_active Abandoned
- 2012-05-25 WO PCT/EP2012/059879 patent/WO2012160199A1/en active Application Filing
- 2012-05-25 KR KR1020137034545A patent/KR20140033171A/ko not_active Application Discontinuation
- 2012-05-25 MX MX2013013862A patent/MX349119B/es active IP Right Grant
- 2012-05-25 CN CN201710173241.XA patent/CN107050445A/zh active Pending
- 2012-05-25 EP EP12723216.3A patent/EP2714076A1/en not_active Withdrawn
- 2012-05-25 CN CN201280031821.0A patent/CN103619349A/zh active Pending
- 2012-05-25 AU AU2012260807A patent/AU2012260807B2/en not_active Ceased
-
2013
- 2013-11-07 IL IL229307A patent/IL229307A0/en unknown
- 2013-11-26 CO CO13277999A patent/CO6811814A2/es unknown
-
2016
- 2016-08-05 AU AU2016210743A patent/AU2016210743A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012260807B2 (en) | 2016-05-12 |
JP2014515367A (ja) | 2014-06-30 |
MX349119B (es) | 2017-07-12 |
BR112013030236A2 (pt) | 2016-12-06 |
CN107050445A (zh) | 2017-08-18 |
MX2013013862A (es) | 2014-01-23 |
WO2012160199A1 (en) | 2012-11-29 |
SG194950A1 (en) | 2013-12-30 |
EA201391515A1 (ru) | 2014-05-30 |
CN103619349A (zh) | 2014-03-05 |
US20140112953A1 (en) | 2014-04-24 |
IL229307A0 (en) | 2014-01-30 |
CA2837145A1 (en) | 2012-11-29 |
AU2016210743A1 (en) | 2016-08-25 |
KR20140033171A (ko) | 2014-03-17 |
PE20140646A1 (es) | 2014-05-29 |
EP2714076A1 (en) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL262123A (en) | Influenza virus vaccines and their uses | |
IL261204A (en) | Influenza virus vaccines and their use | |
CO6811814A2 (es) | Vacuna de virus dengue inactivado | |
HK1199211A1 (en) | Influenza virus vaccines and uses thereof | |
DK3424532T3 (da) | Influenzavirus-antistofsammensætninger | |
DK3447131T3 (da) | Influenza a-virusmutanter | |
BR112014033077A2 (pt) | combinação de vacina. | |
DK2793937T3 (da) | Vacciner mod HPV | |
CO6821947A2 (es) | Inhibidores del virus de la hepatitis c | |
SMT201600082B (it) | Vaccino pcsk9 | |
CO6940424A2 (es) | Inhibidores del virus de la hepatitis c | |
DK2935313T3 (da) | Vacciner mod hepatitis B-virus | |
CO6821952A2 (es) | Inihibidores del virus de la hepatitis c | |
BR112013017488A2 (pt) | peptídeos imunogênicos multiméricos e monoméricos | |
SMT201700046B (it) | Micobatterio ricombinante come vaccino | |
BR112013001514A2 (pt) | vacina para influenza | |
DK2748612T3 (da) | Forbedret vaccinediagnostik | |
DK2686011T3 (da) | Ipn-vaccine | |
SG10201702292YA (en) | Novel attenuated dengue virus strains for vaccine application | |
CU24112B1 (es) | Antígenos vacunales quiméricos contra el virus de la hepatitis c | |
HK1201283A1 (en) | Influenza c virus and vaccine | |
HK1197268A1 (en) | Recombinant swine influenza virus and uses thereof | |
EP2749287A4 (en) | INHIBITOR OF INFLUENZA VIRUS INFECTION | |
HK1209647A1 (en) | Dengue virus vaccine composition | |
AU2013369626A1 (en) | Dengue virus vaccine composition |